SG11202108312PA - Method of safe administration of phosphorylated tau peptide vaccine - Google Patents
Method of safe administration of phosphorylated tau peptide vaccineInfo
- Publication number
- SG11202108312PA SG11202108312PA SG11202108312PA SG11202108312PA SG11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA SG 11202108312P A SG11202108312P A SG 11202108312PA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide vaccine
- phosphorylated tau
- tau peptide
- safe administration
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802870P | 2019-02-08 | 2019-02-08 | |
| PCT/US2020/017235 WO2020163730A2 (en) | 2019-02-08 | 2020-02-07 | Method of safe administration of phosphorylated tau peptide vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108312PA true SG11202108312PA (en) | 2021-08-30 |
Family
ID=69780323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108312PA SG11202108312PA (en) | 2019-02-08 | 2020-02-07 | Method of safe administration of phosphorylated tau peptide vaccine |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11684576B2 (ko) |
| EP (1) | EP3920966A2 (ko) |
| JP (1) | JP7541527B2 (ko) |
| KR (1) | KR20210125048A (ko) |
| CN (1) | CN113710269A (ko) |
| AU (1) | AU2020219804A1 (ko) |
| BR (1) | BR112021014794A2 (ko) |
| CA (1) | CA3129252A1 (ko) |
| EA (1) | EA202192203A1 (ko) |
| IL (1) | IL285163A (ko) |
| JO (1) | JOP20210211A1 (ko) |
| MX (1) | MX2021009508A (ko) |
| SG (1) | SG11202108312PA (ko) |
| TW (1) | TW202045204A (ko) |
| WO (1) | WO2020163730A2 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3700556A2 (en) * | 2017-10-25 | 2020-09-02 | Janssen Pharmaceuticals, Inc. | Compositions of phosphorylated tau peptides and uses thereof |
| CA3152239A1 (en) * | 2019-09-23 | 2021-04-01 | Lars Ittner | Treatment of tauopathies |
| GB2600468A (en) * | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| AU2022328342A1 (en) * | 2021-08-12 | 2024-02-22 | Ac Immune Sa | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses |
| WO2023023332A1 (en) * | 2021-08-20 | 2023-02-23 | Thomas Jefferson University | Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| EP0673418B1 (en) | 1992-12-14 | 1998-05-06 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| WO2002004949A2 (en) | 2000-07-11 | 2002-01-17 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
| GB0114719D0 (en) * | 2001-06-15 | 2001-08-08 | Glaxo Group Ltd | Compound |
| EP1474432A1 (en) | 2002-02-04 | 2004-11-10 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| KR100994748B1 (ko) * | 2002-04-19 | 2010-11-17 | 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 | 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물 |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| NO346055B1 (no) | 2005-12-12 | 2022-01-24 | Ac Immune Sa | Antigen konstruksjon, vaksinesammensetning og fremgangsmåte for produksjon derav. |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| CN101965365A (zh) | 2007-10-19 | 2011-02-02 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
| EP2408807B1 (en) | 2009-03-18 | 2021-07-21 | AC Immune SA | Method for therapeutic use |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| JP5917394B2 (ja) | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
| NZ598356A (en) | 2009-07-30 | 2014-06-27 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| EP3527220A1 (en) | 2010-08-12 | 2019-08-21 | AC Immune S.A. | Vaccine engineering |
| AU2011322553B2 (en) | 2010-10-26 | 2015-07-02 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| EP3104870A4 (en) | 2014-02-14 | 2017-09-13 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| BR112016029579A2 (pt) | 2014-06-26 | 2017-08-22 | Janssen Vaccines & Prevention Bv | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos |
| US10112990B2 (en) | 2015-06-05 | 2018-10-30 | Genentech, Inc. | Anti-Tau antibodies and methods of use |
| TW202328181A (zh) | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
| EP3700556A2 (en) | 2017-10-25 | 2020-09-02 | Janssen Pharmaceuticals, Inc. | Compositions of phosphorylated tau peptides and uses thereof |
| JP2021502125A (ja) | 2017-11-09 | 2021-01-28 | ピンテオン セラピューティクス インコーポレイテッド | ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物 |
| MX2021012994A (es) | 2019-04-24 | 2022-03-04 | Janssen Pharmaceuticals Inc | Administracion heterologa de vacunas tau. |
-
2020
- 2020-02-07 EA EA202192203A patent/EA202192203A1/ru unknown
- 2020-02-07 EP EP20710370.6A patent/EP3920966A2/en active Pending
- 2020-02-07 KR KR1020217028336A patent/KR20210125048A/ko active Search and Examination
- 2020-02-07 BR BR112021014794-2A patent/BR112021014794A2/pt unknown
- 2020-02-07 SG SG11202108312PA patent/SG11202108312PA/en unknown
- 2020-02-07 AU AU2020219804A patent/AU2020219804A1/en active Pending
- 2020-02-07 WO PCT/US2020/017235 patent/WO2020163730A2/en unknown
- 2020-02-07 US US16/785,011 patent/US11684576B2/en active Active
- 2020-02-07 JP JP2021546263A patent/JP7541527B2/ja active Active
- 2020-02-07 CA CA3129252A patent/CA3129252A1/en active Pending
- 2020-02-07 CN CN202080027380.1A patent/CN113710269A/zh active Pending
- 2020-02-07 JO JOP/2021/0211A patent/JOP20210211A1/ar unknown
- 2020-02-07 MX MX2021009508A patent/MX2021009508A/es unknown
- 2020-02-10 TW TW109104093A patent/TW202045204A/zh unknown
-
2021
- 2021-07-27 IL IL285163A patent/IL285163A/en unknown
-
2023
- 2023-05-12 US US18/316,829 patent/US20230381108A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20210211A1 (ar) | 2023-01-30 |
| JP2022520060A (ja) | 2022-03-28 |
| US20230381108A1 (en) | 2023-11-30 |
| JP7541527B2 (ja) | 2024-08-28 |
| KR20210125048A (ko) | 2021-10-15 |
| US11684576B2 (en) | 2023-06-27 |
| IL285163A (en) | 2021-09-30 |
| BR112021014794A2 (pt) | 2021-10-05 |
| EA202192203A1 (ru) | 2021-10-20 |
| WO2020163730A2 (en) | 2020-08-13 |
| CA3129252A1 (en) | 2020-08-13 |
| TW202045204A (zh) | 2020-12-16 |
| US20200253873A1 (en) | 2020-08-13 |
| WO2020163730A3 (en) | 2020-09-24 |
| MX2021009508A (es) | 2021-09-08 |
| AU2020219804A1 (en) | 2021-08-19 |
| EP3920966A2 (en) | 2021-12-15 |
| CN113710269A (zh) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285163A (en) | A method for the safe administration of a phosphorylated tau peptide vaccine | |
| SG11202001008RA (en) | Preparation of therapeutic exosomes using membrane proteins | |
| IL291537A (en) | Vaccine preparations containing protein | |
| SG11202001161YA (en) | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 | |
| ZA202108168B (en) | Heterologous administration of tau vaccines | |
| IL267622A (en) | Method for modifying the therapeutic effects of drugs | |
| IL265856B1 (en) | Preparations for administration of aflornithine | |
| IL275639A (en) | Formulation for RNA administration | |
| IL272513A (en) | Lyophilization process for pharmaceutical formulation of medical protein | |
| EP3576764A4 (en) | KRAS PEPTIDE VACCINE COMPOSITIONS AND METHOD OF USE | |
| EP3127552A4 (en) | Microneedle array preparation comprising inactivated whole virus vaccine and method for administering same | |
| EP3703817A4 (en) | ORAL ADMINISTRATION OF GLP-1 PEPTIDE ANALOGA | |
| IL283286A (en) | Pharmaceutical formulations of cyclosporine analogs | |
| EP3525772A4 (en) | FORMULATIONS FOR THE ENTERIC ADMINISTRATION OF THERAPEUTIC AGENTS | |
| EP3414257A4 (en) | PROCESS FOR THE PRODUCTION OF LIRAGLUTIDE WITH THE HELP OF A BAL-LINKER | |
| EP3371212A4 (en) | PEPTIDES AND METHOD FOR TREATING CARDIAC ARREST | |
| IL280883A (en) | Systems for the intestinal transfer of medicinal substances | |
| EP3474826A4 (en) | PHARMACEUTICAL PREPARATION FOR ADMINISTRATION OF PEPTIDES AND PROTEINS | |
| GB201812861D0 (en) | Methods of administering therapy | |
| EP3324990A4 (en) | IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNO-BASED THERAPY | |
| EP3466422A4 (en) | APPLICATION OF Z-BUTYLIDENEPHTHALIDE FOR REINFORCING THE INNATE IMMUNE SYSTEM | |
| SG11202011004RA (en) | Hepatitis b vaccine transnasal administration system | |
| GB202013912D0 (en) | Single-dose live-attenuated YF17D-vectored vaccine against SARS-CoV-2 | |
| GB202010479D0 (en) | Single-dose live-attenuated YF17D-vectored vaccine against SARS-CoV-2 | |
| HK1248724A1 (zh) | 肽或其鹽及其製備方法 |